IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0990248
(2001-11-21)
|
발명자
/ 주소 |
- Ullman, Myron
- Burman, M. Robert
- Kessler, Ronald N.
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
10 인용 특허 :
24 |
초록
▼
A rubber or plastic floor mat has a series of parallel upper ribs (130) on its upper surface which define slots (110) in which respective strips (10) or carpeting or the like are removably held. The strips are retained along their lengths by retaining means which run continually or continuously alon
A rubber or plastic floor mat has a series of parallel upper ribs (130) on its upper surface which define slots (110) in which respective strips (10) or carpeting or the like are removably held. The strips are retained along their lengths by retaining means which run continually or continuously along the slots. The strip retainers include hook-and-loop fastening (e.g., VELCRO), and/or overhanging edges above the strip edges, preferably formed in one-piece fashion along the side of the upper ribs adjacent the slots. The overhangs may be interrupted, e.g., crenelated as seen from above, and may include bevels.
대표청구항
▼
A rubber or plastic floor mat has a series of parallel upper ribs (130) on its upper surface which define slots (110) in which respective strips (10) or carpeting or the like are removably held. The strips are retained along their lengths by retaining means which run continually or continuously alon
A rubber or plastic floor mat has a series of parallel upper ribs (130) on its upper surface which define slots (110) in which respective strips (10) or carpeting or the like are removably held. The strips are retained along their lengths by retaining means which run continually or continuously along the slots. The strip retainers include hook-and-loop fastening (e.g., VELCRO), and/or overhanging edges above the strip edges, preferably formed in one-piece fashion along the side of the upper ribs adjacent the slots. The overhangs may be interrupted, e.g., crenelated as seen from above, and may include bevels. tion as defined in claim 1, comprising a microsphere. 3. A delivery composition as defined in claim 2, wherein said microsphere comprises a microcapsule. 4. A delivery composition as defined in claim 2, wherein said microsphere has a diameter of less than about 10 μm. 5. The delivery composition as defined in claim 1, wherein said peptide is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-II, insulin, heparin, calcitonin, erythropoietin, atrial naturetic factor, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, vancomycin, or any combination of any of the foregoing. 6. A delivery composition as defined in claim 5, wherein said peptide is selected from the group consisting of an interferon, interleukin-II, insulin, heparin, calcitonin, oxytocin, vasopressin, vancomycin, or any combination of any of the foregoing. 7. A delivery composition as defined in claim 1, wherein said diketopiperazine is derived from two α-amino acids. 8. A delivery composition as defined in claim 7, wherein said two α-amino acids from which said diketopiperazine is derived are the same. 9. A delivery composition as defined in claim 7, wherein said diketopiperazine is prepared by the thermal condensation of said two α-amino acids from which said diketopiperazine is derived. 10. A delivery composition as defined in claim 1, further comprising (c) at least one enzyme inhibitor. 11. A pharmacological composition comprising: (a) at least one peptide; and (b) at least one diketopiperazine having the formula: wherein R1and R2are C1-C24alkyl or C1-C24alkenyl and have at least one functional group selected from the group consisting of oxygen and amide groups; both R1and R2,optionally, are substituted with C1-C4alkyl, C1-C4alkenyl, C1-C4alkoxy, --OH, --SH, and --CO2R3or any combination thereof; wherein R3is hydrogen, C1-C4alkyl, or C1-C4alkenyl; R1and R2are interrupted by oxygen, nitrogen, sulfur, or any combination thereof. 12. A dosage unit form comprising: (A) a delivery composition as defined in claim 1; and (B)(a) an excipient, (b) a diluent, (c) a disintegrant, (d) a lubricant, (e) a plasticizer, (f) a colorant, (g) a dosing vehicle, or (h) any combination thereof. 13. A dosage unit form as defined in claim 11, comprising an oral dosage unit form. 14. A method for administering a peptide to an animal in need thereof, said method comprising administering orally to said animal, a composition as defined in claim 1. 15. A method for preparing microspheres containing an active agent, said method comprising: (A) solubilizing, in a solvent, at least one diketopiperazine having the formula: wherein R1and R2are C1-C24alkyl or C1-C24alkenyl and have at least one functional group selected from the group consisting of oxygen and amide groups; both R1and R2,optionally, are substituted with C1-C4alkyl, C1-C4alkenyl, C1-C4alkoxy, --OH, --SH, and --CO2R3or any combination thereof; wherein R3is hydrogen, C1-C4alkyl, or C1-C4alkenyl; R1and R2are interrupted by oxygen, nitrogen, sulfur, or any combination thereof, to yield a diketopiperazine solution; and (B) contacting said diketopiperazine solution with said a peptide and a precipitator solution in which said diketopiperazine is insoluble. 16. A method as defined in claim 15, wherein said diketopiperazine solution has a pH within a fi rst range and said precipitator solution has a pH within a second range, said first range being different than said second range. 17. A delivery composition as defined in claim 1, wherein R1and R2are interrupted by nitrogen. 18. A delivery composition as defined in claim 17, wherein R1and R2are substituted with --CO2R3. 19. A delivery composition as defined in claim 18, wherein R3is hydrogen. 20. A delivery composition as defined in claim 17, wherein the functional group is oxygen. 21. A delivery composition as defined in claim 17, wherein the functional group is an amide group. 22. A delivery composition as defined in claim 1, wherein R1and R2comprise an amide group. 23. A delivery composition as defined in claim 1, wherein the peptide is insulin. 24. A delivery composition as defined in claim 1, wherein the peptide is calcitonin. 25. A delivery composition as defined in claim 1, wherein the delivery composition is a solution comprising from about 10 to about 2000 mg of the diketopiperazine per ml of solution. 26. The delivery composition of claim 25, wherein the solution comprises from about 75 to about 500 mg of the diketopiperazine per ml of solution.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.